Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents

References

• Loewith R, Hall MN. Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics 2011;189:1177–1201.
   PubMed Web of Science ®Google Scholar
• Loewith R, Jacinto E, Wullschleger S, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002;10:457–468.
   PubMed Web of Science ®Google Scholar
• Mamane Y, Petroulakis E, LeBacquer O, et al. mTOR, translation initiation and cancer. Oncogene 2006;25:6416–6422.
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424–430.
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471–484.
   PubMed Web of Science ®Google Scholar
• Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer. Oncogene 2013;32:3923–3932.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274–293.
   PubMed Web of Science ®Google Scholar
• Gentzler RD, Altman JK, Platanias LC. An overview of the mTOR pathway as a target in cancer therapy. Expert Opin Ther Targets 2012; 16:481–489.
   PubMed Web of Science ®Google Scholar
• Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011; 2:510–517.
   Google Scholar
• Alayev A, Holz MK. mTOR signaling for biological control and cancer. J Cell Physiol 2013;228:1658–1664.
   PubMed Web of Science ®Google Scholar
• Yu Y, Yoon SO, Poulogiannis G, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 2011;332:1322–1326.
   PubMed Web of Science ®Google Scholar
• Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011;332:1317–1322.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27:2278–2287.
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926–1945.
   PubMed Web of Science ®Google Scholar
• Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008;27(Suppl. 2):S43–S51.
   PubMedGoogle Scholar
• Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998;31:335–340.
   PubMed Web of Science ®Google Scholar
• Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721–726.
   Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335–348.
   PubMed Web of Science ®Google Scholar
• Benjamin D, Colombi M, Moroni C, et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011;10:868–880.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159–168.
   PubMed Web of Science ®Google Scholar
• Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008;14:1286–1290.
   PubMed Web of Science ®Google Scholar
• Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010;30:1044–1056.
   PubMed Web of Science ®Google Scholar
• Mita M, Sankhala K, Abdel-Karim I, et al. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 2008;17:1947–1954.
   PubMed Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822–3829.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–456.
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–2281.
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–523.
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520–529.
   PubMed Web of Science ®Google Scholar
• Mohindra NA, Giles FJ, Platanias LC. Use of mTOR inhibitors in the treatment of malignancies. Expert Opin Pharmacother 2014;15: 979–990.
   PubMed Web of Science ®Google Scholar
• Choo AY, Yoon SO, Kim SG, et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008;105:17414–17419.
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807–826.
   PubMed Web of Science ®Google Scholar
• Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009;8:567–572.
   PubMed Web of Science ®Google Scholar
• Armengol G, Rojo F, Castellvi J, et al. 4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications. Cancer Res 2007;67:7551–7555.
   PubMed Web of Science ®Google Scholar
• Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004;14:1650–1656.
   PubMed Web of Science ®Google Scholar
• Shi Y, Yan H, Frost P, et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005;4:1533–1540.
   PubMed Web of Science ®Google Scholar
• Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166:213–223.
   PubMed Web of Science ®Google Scholar
• Wang X, Yue P, Kim YA, et al. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008;68:7409–7418.
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500–1508.
   PubMed Web of Science ®Google Scholar
• Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052–7058.
   PubMed Web of Science ®Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065–3074.
   PubMed Web of Science ®Google Scholar
• Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle 2011;10:2305–2316.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9–22.
   PubMed Web of Science ®Google Scholar
• Treins C, Warne PH, Magnuson MA, et al. Rictor is a novel target of p70 S6 kinase-1. Oncogene 2010;29:1003–1016.
   PubMed Web of Science ®Google Scholar
• Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009;29:5657–5670.
   PubMed Web of Science ®Google Scholar
• Khokhar NZ, Altman JK, Platanias LC. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol 2011;23: 578–586.
   PubMed Web of Science ®Google Scholar
• Nelson V, Altman JK, Platanias LC. Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer. Expert Opin Investig Drugs 2013;22:715–722.
   PubMed Web of Science ®Google Scholar
• Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70:288–298.
   PubMed Web of Science ®Google Scholar
• Sini P, James D, Chresta C, et al. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy 2010;6:553–554.
   PubMed Web of Science ®Google Scholar
• Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res 2011;71: 1573–1583.
   PubMed Web of Science ®Google Scholar
• Li H, Lin J, Wang X, et la. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Res Treat 2012;134:1057–1066.
   PubMed Web of Science ®Google Scholar
• Gupta M, Hendrickson AE, Yun SS, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 2012;119:476–487.
   PubMed Web of Science ®Google Scholar
• Altman JK, Sassano A, Kaur S, et al. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011;17:4378–4388.
   PubMed Web of Science ®Google Scholar
• Vakana E, Sassano A, Platanias LC. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy 2010;6:966–967.
   PubMed Web of Science ®Google Scholar
• Carayol N, Vakana E, Sassano A, et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010;107:12469–12474.
   PubMed Web of Science ®Google Scholar
• Bhagwat SV, Gokhale PC, Crew AP, et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 2011;10: 1394–1406.
   PubMed Web of Science ®Google Scholar
• Guichard S, Howard Z, Heathcote D. AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer. Cancer Res 2012;72(Suppl.): Abstract 917.
   PubMed Web of Science ®Google Scholar
• Willems L, Chapuis N, Puissant A, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012;26:1195–1202.
   PubMed Web of Science ®Google Scholar
• Pike KG, Malagu K, Hummersone MG, et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 2013;23:1212–1216.
   PubMed Web of Science ®Google Scholar
• Naing A, Aghajanian C, Raymond E, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer 2012;107:1093–1099.
   PubMed Web of Science ®Google Scholar
• Asahina H, Nokihara H, Yamamoto N, et la. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. Invest New Drugs 2013;31:677–684.
   PubMed Web of Science ®Google Scholar
• Banerji U, Dean E, Gonzalez M. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors. J Clin Oncol 2012;30(15 Suppl.): Abstract 3004.
   Web of Science ®Google Scholar
• AZD2014. AstraZeneca. Available from: www.ncats.nih.gov/files/AZD2014.pdf
   Google Scholar
• Tan DS, Dumez H, Olmos D, et al. First in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. J Clin Oncol 2010;28(15 Suppl.): Abstract 3006.
   Web of Science ®Google Scholar
• Jessen K, Wang S, Kessler L, et al. INK128 is a potent and selective TORC1/2 inhibitor with broad oral anti-tumor activity. Presented at: AACR 2009 Molecular Targets and Cancer Therapeutics Meeting, November 2009, Boston, MA; poster B148.
   Google Scholar
• Janes MR, Vu C, Mallya S, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia 2013;27:586–594.
   PubMed Web of Science ®Google Scholar
• Maiso P, Liu Y, Morgan B, et al. Defining the role of TORC1/2 in multiple myeloma. Blood 2011;118:6860–6870.
   PubMed Web of Science ®Google Scholar
• Pourdehnad M, Truitt ML, Siddiqi IN, et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci USA 2013;110:11988–11993.
   PubMed Web of Science ®Google Scholar
• Zhang H, Dou J, Yu Y, et al. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis 2015;20:50–62.
   PubMed Web of Science ®Google Scholar
• Lou HZ, Weng XC, Pan HM, et al. The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells. Biochem Biophys Res Commun 2014;450:973–978.
   PubMed Web of Science ®Google Scholar
• Kang MH, Reynolds CP, Maris JM, et al. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer 2014;61:1486–1489.
   PubMed Web of Science ®Google Scholar
• Ingels A, Zhao H, Thong AE, et al. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer 2014;134:2322–2329.
   PubMed Web of Science ®Google Scholar
• Hayman TJ, Wahba A, Rath BH, et al. The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells. Clin Cancer Res 2014;20:110–119.
   PubMed Web of Science ®Google Scholar
• Gild ML, Landa I, Ryder M, et al. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocr Relat Cancer 2013;20:659–667.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Siegel D, Vij R, et al. MLN0128 (INK128), an investigational oral dual TORC1/2 inhibitor, in patients with relapsed or refractory multiple myeloma, non-Hodgkin's lymphoma, or Waldenstrom macroglobulinemia: preliminary results from a phase I dose-escalation study. Blood 2012;120(Suppl. 1): Abstract 4038.
   PubMed Web of Science ®Google Scholar